Revvity, Inc. (RVTY) is slated to report third-quarter 2024 results on Nov. 04, before market open.In the last reported quarter, the company delivered a positive earnings surprise of 7.96%. RVTY’s earnings beat estimates in three of the trailing four quarters and missed the same in one, delivering an average surprise of 5.02%.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.Q3 EstimatesThe Zacks Consensus Estimate for revenues is pegged at $677.6 million, up 1% compared with the prio ...

Revvity, Inc. (RVTY) has launched Revvity Transcribe AI, an optical character recognition (OCR) service designed to convert handwritten text on test request forms into digital data.Revvity Transcribe AI meets laboratories' need for fast and accurate processing of test request forms. This automated service securely integrates the data into lab information systems, streamlining the process and reducing manual work. The service is expected to improve data entry speed by 40% and is particularly beneficial for n ...

Revvity, Inc. (RVTY) announced the launch of the in-vitro diagnostic EURORealTime APOE assay in European countries that accept the CE mark on Oct. 2. The assay will likely enable accurate genotyping of the APOE gene. It is worth mentioning that APOE genotyping allows the assessment of a patient's risk for side effects before the start of an anti-amyloid (beta) therapy in Alzheimer's disease (AD). The latest launch in European countries that accept the CE mark is expected to significantly boost Revvity's EUR ...

Revvity, Inc. (RVTY) is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by its solid second-quarter 2024 performance and focus on artificial intelligence (AI), is expected to contribute further. Headwinds resulting from foreign exchange volatility and integration risks are major downsides. This Zacks Rank #3 (Hold) company's shares have gained 13.4% year to date compared with 0.7% growth of the industry. The S&P 500 has increased 20.8% during the sa ...

Revvity, Inc. (RVTY) is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by its solid second-quarter 2024 performance and focus on artificial intelligence (AI), is expected to contribute further. Headwinds resulting from foreign exchange volatility and integration risks are major downsides. This Zacks Rank #3 (Hold) company's shares have gained 9.1% year to date compared with 0.6% growth of the industry.The S&P 500 has increased 15% during the same t ...

Investors with an interest in Medical Services stocks have likely encountered both Pediatrix Medical Group (MD) and Revvity (RVTY) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores work ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________ FORM 10-Q _______________________________________ (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | |----------------------------------------------------------------------- ...

Revenue Details Revvity reports under two operating segments — Life Sciences and Diagnostics. Adjusted operating income amounted to $112.4 million, down 12% from the prior-year quarter. Margin Analysis The company exited the second quarter of 2024 with cash and cash equivalents of $1.95 billion compared with $1.70 billion in the prior-quarter end. Price Performance Some better-ranked stocks in the broader medical space that have announced quarterly results are Boston Scientific Corporation (BSX) , Hologic ( ...

Key Takeaways Revvity reported second-quarter profit and sales that exceeded estimates on higher demand for its diagnostic products. The medical equipment maker posted a 1.4% year-over-year increase in revenue at its Diagnostics segment, while revenue at its Life Sciences division declined. Revvity raised its full-year adjusted EPS guidance. Revvity (RVTY) shares advanced Monday after the medical equipment maker formerly known as PerkinElmer posted better-than-expected results and boosted its profit guidanc ...

Revvity, Inc. (NYSE:RVTY) Q2 2024 Earnings Conference Call July 29, 2024 8:00 AM ET Company Participants Steve Willoughby - SVP, IR Prahlad Singh - President & CEO Max Krakowiak - SVP & CFO Conference Call Participants Patrick Donnelly - Citi Jack Meehan - Nephron Research Puneet Souda - Leerink Partners Vijay Kumar - Evercore Matt Sykes - Goldman Sachs Dan Brennan - TD Cowen Catherine Schulte - Baird Luke Sergott - Barclays Michael Ryskin - Bank of America Paul Knight - KeyBanc Rachel Vatnsdal - JP Morgan ...